Detalhe da pesquisa
1.
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Cancer Sci
; 111(4): 1314-1323, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31971321
2.
Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells.
Haematologica
; 103(6): 959-971, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545344
3.
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Blood
; 123(1): 15-25, 2014 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24169824
4.
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Blood
; 122(11): 1900-13, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23896410
5.
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Blood
; 122(18): 3138-48, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24030378
6.
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Nat Commun
; 15(1): 4144, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38755140
7.
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling.
Front Oncol
; 12: 948548, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36033464
8.
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
Blood
; 114(3): 659-62, 2009 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-19458358
9.
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
Leukemia
; 35(8): 2220-2231, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542479
10.
A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Int J Hematol
; 112(2): 223-233, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564243
11.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
J Immunother Cancer
; 6(1): 116, 2018 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30396365
12.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Oncogene
; 37(39): 5269-5280, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29855615
13.
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.
Cancer Res
; 77(16): 4402-4413, 2017 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28625976
14.
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.
Cell Stem Cell
; 15(4): 431-446, 2014 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25280219
15.
Signal Transduction Inhibitors as Promising Anticancer Agents.
Biomed Res Int
; 2015: 584170, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26090424
16.
A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?
Cell Cycle
; 9(9): 1690-6, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20404504
17.
A critical role for Lyn in acute myeloid leukemia.
Blood
; 111(4): 2269-79, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18056483
18.
[The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia]. / La voie PI3K/Akt/mTOR: une nouvelle cible thérapeutique dans le traitement des leucémies aiguës myéloïdes.
Bull Cancer
; 93(5): 445-7, 2006 May.
Artigo
em Francês
| MEDLINE | ID: mdl-16777621
19.
mTOR, a new therapeutic target in acute myeloid leukemia.
Cell Cycle
; 4(11): 1540-9, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16205124
20.
Antileukemic activity of rapamycin in acute myeloid leukemia.
Blood
; 105(6): 2527-34, 2005 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15550488